Bicara Therapeutics Share Price

NASDAQ: BCAX

Small Cap

$11.49

+0.11

(+1.01%)

Live

as on September 16, 2025 at 10:38 pm IST

$₹

Bicara Therapeutics Stock Performance

as on September 16, 2025 at 10:38 pm IST

Day's Low
Day's High
$11.37
Day's Price Range
$11.65
$11.49
1.04%
Downside
1.39%
Upside
52 Week's Low
52 Week's High
$7.8
52-Week Price Range
$28.09
$11.49
32.11%
Downside
144.47%
Upside

Bicara Therapeutics share price movements today

Previous Close: $11.38
Open: $11.37
Volume: 167.6K
Day's Low - High: $11.37 - $11.65
52 Week Low - High: $7.8 - $28.09

Bicara Therapeutics Historical Returns

1 Month Return: -2.23 %
3 Month Return: + 13.8 %
1 Year Return: -55.21 %
3 Year Return: 0 %
5 Year Return: 0 %

Bicara Therapeutics Stock Fundamentals & Key Indicators

Check Bicara Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$634.0M

EPS (TTM)

-2.2213

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

0.00%

Bicara Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Bicara Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Bicara Therapeutics	NA	$634.0M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	251.26%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.2B	47.46%	28.09	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.6B	0.6%	14.1	31.37%

Stock Returns calculator for Bicara Therapeutics Stock including INR - Dollar returns

The Bicara Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Bicara Therapeutics investment value today

Current value as on today

₹50,086

Returns

₹49,914

(-49.91%)

Returns from Bicara Therapeutics Stock

₹54,782 (-54.78%)

Dollar Returns*

₹4,867 (+4.87%)

Bicara Therapeutics Stock's Interest Amongst Investors

Search interest for Bicara Therapeutics Stock has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 17, 2025 to September 16, 2025

Change:-33% versus previous 30 day period

Bicara Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	-	0	0	0	0	0	0
Operating Income	-9	-13	-17	-17	-20	-26	-41	-32
EBITDA	-9	-25	-17	-17	-20	-26	-41	-32
Interest Expense	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0
Income Before Tax	-22	-12	-14	-14	-17	-20	-36	-27
Income Tax Expense	-	0	0	0	-	0	0	0
Net Income	-22	-12	-14	-14	-17	-20	-36	-27
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Bicara Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-
Gross Profit	0	0	0
Operating Income	-37	-39	-82
EBITDA	-37	-51	-67
Interest Expense	0	-	-
Depreciation	0	0	0
Income Before Tax	-37	-51	-67
Income Tax Expense	0	0	0
Net Income	-37	-51	-67
Net Profit Margin	0.00%	0.00%	0.00%

Bicara Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-8	-22	-12	-14	-14	-17	-20	-36	-27
Operating Cash Flow	-13	-10	-8	-14	-12	-17	-30	-28	-25
Investing Cash Flow	-	0	0	0	0	0	0	-	-
Financing Cash Flow	18	39	194	0	0	334	0	0	0
Change in Cash	14	29	186	-14	203	316	-31	-27	-25

Bicara Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2023	Dec 2024
Net Income	-51	-67
Operating Cash Flow	-45	-74
Investing Cash Flow	0	0
Financing Cash Flow	272	334
Change in Cash	226	259

Insights on Bicara Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 70.6% return, outperforming this stock by 125.8%
NEGATIVE IMPACT
Price Dip
In the last 7 days, BCAX stock has moved down by -8.7%

About Bicara Therapeutics

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR), directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation and the immunosuppressive TGF-b signaling within the tumor microenvironment. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need. Its platform is designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site.

Organisation	Bicara Therapeutics
Headquarters	116 Huntington Avenue, Boston, MA, United States, 02116
CEO	Dr. Claire Mazumdar Clemon M.B.A., Ph.D.
E-voting on shares	Click here to vote

Key Management of Bicara Therapeutics

Name	Title
Mr. Ivan Hyep M.B.A.	Chief Financial Officer
Ms. Angela Windt	VP & Head of Regulatory Affairs
Mr. Jean-Paul Rodrique	Senior VP & Global Head of Quality Assurance
Dr. Jeltje Schulten M.B.A., M.D.	Senior Vice President of Clinical & Medical Affairs
Dr. Claire Mazumdar Clemon M.B.A., Ph.D.	CEO & Director
Mr. Ryan Cohlhepp Pharm.D.	President, COO & Director
Ms. Lara S. Meisner J.D.	Chief Legal Officer & Corporate Secretary
Ms. Rachel Salazar	SVP of R&D Strategy and Operations
Ms. Sathish Hasige Ph.D.	Senior VP and Head of Technical Operations & Supply Chain
Dr. David Raben M.D.	Chief Medical Officer

FAQs

What is Bicara Therapeutics share price today?

Bicara Therapeutics share price today is $11.49 as on September 16, 2025 at 10:38 pm IST. Bicara Therapeutics share today touched a day high of $11.65 and a low of $11.37.

What is the 52 week high and 52 week low for Bicara Therapeutics share?

Bicara Therapeutics share touched a 52 week high of $28.09 on November 6, 2024 and a 52 week low of $7.8 on May 23, 2025. Bicara Therapeutics stock price today i.e. September 16, 2025 at 10:38 pm IST is trending at $11.49,which is 59.10% down from its 52 week high and 47.31% up from its 52 week low.

What is Bicara Therapeutics's market capitalisation today?

Bicara Therapeutics market capitalisation is $0.00T as on September 16, 2025 at 10:38 pm IST.

How to invest in Bicara Therapeutics Stock (BCAX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Bicara Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Bicara Therapeutics Shares that will get you 0.1305 shares as per Bicara Therapeutics share price of $11.49 per share as on September 16, 2025 at 10:38 pm IST.

What is the minimum amount required to buy Bicara Therapeutics Stock (BCAX) from India?

Indian investors can start investing in Bicara Therapeutics (BCAX) shares with as little as ₹88.042 or $1 (as of September 16, 2025 at 10:39 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹880.42 in Bicara Therapeutics stock (as per the Rupee-Dollar exchange rate as on September 16, 2025 at 10:39 pm IST). Based on Bicara Therapeutics share’s latest price of $11.49 as on September 16, 2025 at 10:38 pm IST, you will get 0.8703 shares of Bicara Therapeutics. Learn more about fractional shares .